1. Home
  2. PCB vs ZURA Comparison

PCB vs ZURA Comparison

Compare PCB & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PCB Bancorp

PCB

PCB Bancorp

HOLD

Current Price

$22.46

Market Cap

325.6M

Sector

Finance

ML Signal

HOLD

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$4.50

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCB
ZURA
Founded
2003
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
325.6M
252.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PCB
ZURA
Price
$22.46
$4.50
Analyst Decision
Hold
Strong Buy
Analyst Count
2
8
Target Price
$24.50
$11.38
AVG Volume (30 Days)
26.5K
439.9K
Earning Date
01-29-2026
11-13-2025
Dividend Yield
3.57%
N/A
EPS Growth
43.50
N/A
EPS
2.41
N/A
Revenue
$107,743,000.00
N/A
Revenue This Year
$21.55
N/A
Revenue Next Year
$8.65
N/A
P/E Ratio
$9.30
N/A
Revenue Growth
13.61
N/A
52 Week Low
$16.00
$0.97
52 Week High
$24.04
$4.68

Technical Indicators

Market Signals
Indicator
PCB
ZURA
Relative Strength Index (RSI) 50.16 68.03
Support Level $23.03 $4.00
Resistance Level $24.04 $4.44
Average True Range (ATR) 0.63 0.25
MACD -0.09 0.05
Stochastic Oscillator 45.33 92.46

Price Performance

Historical Comparison
PCB
ZURA

About PCB PCB Bancorp

PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Share on Social Networks: